Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

Liz Meszaros, MDLinx

Superbugs and Superdrugs USA

Iselin, New Jersey, United States | November 13-14, 2017


Iselin, NJ, November 13, 2017--CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) is a public/private partnership between Wellcome Trust and the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA).


The partnership was launched in July 2016 to address and fill the gaps in antibiotic research, development, and innovation in improving the diagnosis and treatment of drug-resistant infections. John H. Rex, MD, FACP, chief medical officer, F2G Ltd., Manchester, UK, explains the inception of CARB-X, its goals, and achievements.